Lhermitte's sign as a complication of cisplatin-containing chemotherapy for testicular cancer.
Lhermitte's sign is reported in 14 patients receiving chemotherapy for metastatic testicular cancer. In six patients the typical symptoms appeared during chemotherapy: in five patients within 1 month of treatment and in one patient at 2 months. The duration of symptoms ranged from 2 to approximately 8 months. No patient had received radiotherapy to the cervical or dorsal spinal cord. The complication is ascribed to cisplatin, the only drug common to all 14 patients.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects*; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D010292:Paresthesia / Q000139:chemically induced*; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced; D011928:Raynaud Disease / Q000139:chemically induced; D013736:Testicular Neoplasms / Q000188:drug therapy*; D013997:Time Factors; D014747:Vinblastine / Q000008:administration & dosage
D001761:Bleomycin; D014747:Vinblastine; D005047:Etoposide; D002945:Cisplatin